These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 20346035)

  • 1. Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer?
    Remzi M; Haese A; Van Poppel H; De La Taille A; Stenzl A; Hennenlotter J; Marberger M
    BJU Int; 2010 Oct; 106(8):1138-42. PubMed ID: 20346035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
    Haese A; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; van Gils MP; Schalken JA
    Eur Urol; 2008 Nov; 54(5):1081-8. PubMed ID: 18602209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?
    Ploussard G; Haese A; Van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Bastien L; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; Van Gils MP; Schalken JA; de La Taille A
    BJU Int; 2010 Oct; 106(8):1143-7. PubMed ID: 20230386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological patterns of prostate biopsy in men with fluctuations of prostate cancer gene 3 score: a preliminary report.
    De Luca S; Passera R; Cappia S; Bollito E; Randone DF; Porpiglia F
    Anticancer Res; 2015 Apr; 35(4):2417-22. PubMed ID: 25862908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluctuation in prostate cancer gene 3 (PCA3) score in men undergoing first or repeat prostate biopsies.
    De Luca S; Passera R; Cappia S; Bollito E; Randone DF; Milillo A; Papotti M; Porpiglia F
    BJU Int; 2014 Dec; 114(6b):E56-E61. PubMed ID: 24472071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histological chronic prostatitis and high-grade prostate intra-epithelial neoplasia do not influence urinary prostate cancer gene 3 score.
    De Luca S; Passera R; Milillo A; Coda R; Randone DF
    BJU Int; 2012 Dec; 110(11 Pt B):E778-82. PubMed ID: 23116408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.
    Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J
    Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting.
    Adam A; Engelbrecht MJ; Bornman MS; Manda SO; Moshokoa E; Feilat RA
    BJU Int; 2011 Dec; 108(11):1728-33. PubMed ID: 21507188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients.
    Goode RR; Marshall SJ; Duff M; Chevli E; Chevli KK
    Prostate; 2013 Jan; 73(1):48-53. PubMed ID: 22585386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.
    Nakanishi H; Groskopf J; Fritsche HA; Bhadkamkar V; Blase A; Kumar SV; Davis JW; Troncoso P; Rittenhouse H; Babaian RJ
    J Urol; 2008 May; 179(5):1804-9; discussion 1809-10. PubMed ID: 18353398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimising repeat prostate biopsy decisions and procedures.
    Kirby R; Fitzpatrick JM
    BJU Int; 2012 Jun; 109(12):1750-4. PubMed ID: 22192873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.
    Gittelman MC; Hertzman B; Bailen J; Williams T; Koziol I; Henderson RJ; Efros M; Bidair M; Ward JF
    J Urol; 2013 Jul; 190(1):64-9. PubMed ID: 23416644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy?
    Tombal B; Andriole GL; de la Taille A; Gontero P; Haese A; Remzi M; Speakman M; Smets L; Stoevelaar H
    Urology; 2013 May; 81(5):998-1004. PubMed ID: 23523291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.
    Ferro M; Bruzzese D; Perdonà S; Mazzarella C; Marino A; Sorrentino A; Di Carlo A; Autorino R; Di Lorenzo G; Buonerba C; Altieri V; Mariano A; Macchia V; Terracciano D
    Clin Chim Acta; 2012 Aug; 413(15-16):1274-8. PubMed ID: 22542564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance.
    van Poppel H; Haese A; Graefen M; de la Taille A; Irani J; de Reijke T; Remzi M; Marberger M
    BJU Int; 2012 Feb; 109(3):360-6. PubMed ID: 21883822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCA3: a molecular urine assay for predicting prostate biopsy outcome.
    Deras IL; Aubin SM; Blase A; Day JR; Koo S; Partin AW; Ellis WJ; Marks LS; Fradet Y; Rittenhouse H; Groskopf J
    J Urol; 2008 Apr; 179(4):1587-92. PubMed ID: 18295257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy.
    De Luca S; Passera R; Bollito E; Manfredi M; Scarpa RM; Sottile A; Randone DF; Porpiglia F
    Anticancer Res; 2014 Dec; 34(12):7159-65. PubMed ID: 25503144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prostate Cancer gene 3 assay: indications for use in clinical practice.
    Schilling D; de Reijke T; Tombal B; de la Taille A; Hennenlotter J; Stenzl A
    BJU Int; 2010 Feb; 105(4):452-5. PubMed ID: 19930176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can the number of cores with high-grade prostate intraepithelial neoplasia predict cancer in men who undergo repeat biopsy?
    Naya Y; Ayala AG; Tamboli P; Babaian RJ
    Urology; 2004 Mar; 63(3):503-8. PubMed ID: 15028446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
    Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J
    Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.